Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options has recently announced the addition of a market study “ Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options , is a comparative analysis of the global market.

GBI Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).

The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval) are expected to have a significant impact on the market size. Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period.

The emerging treatment challenges in the current treatment landscape (which include, treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the market is set to increase a modest pace due to the patent expiry of the gold-standard therapy during the forecast period.

Download The sample Copy Of This Report:


The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. It includes:

A brief introduction to NHL, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms

In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy

A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target

Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type

Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets

Discussion of the drivers of and barriers to market growth

In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

Understand the NHL pipeline and the factors that indicate that it is becoming more innovative

Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be

Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates

Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the NHL market

Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Symptoms

2.2 Etiology

2.3 Pathophysiology

2.4 Diagnosis

2.4.1 Biopsy

2.4.2 Laboratory molecular tests

2.4.3 Imaging tests

2.5 Classification

2.5.1 B-Cell Lymphomas

2.5.2 T-Cell Lymphoma

2.6 Epidemiology

2.7 Prognosis and Disease Staging

2.7.1 Staging

2.8 Treatment Options

2.8.1 Surgery and Radiation Therapy

2.8.2 Stem Cell Transplantation

2.8.3 Pharmacological

2.8.4 Treatment Algorithms and Prescribing Habits

2.9 GBI Research Report Guidance

3 Marketed Products

3.1 Therapeutic Landscape

3.2 Targeted/Immunotherapies

3.2.1 Rituxan/Mabthera (rituximab) – Roche

3.2.2 Adcetris (Brentuximab vedotin) – Seattle Genetics/Millennium

3.2.3 Zevalin (ibritumomab tiuxetan) – Spectrum Pharmaceuticals

3.2.4 Revlimid (lenalidomide) – Celgene

3.2.5 Velcade (bortezomib) – Millennium/Johnson-Johnson

3.2.6 Istodax (romidepsin) – Celgene

3.2.7 Zolinza (vorinostat) – Merck

3.2.8 Zydelig (idelalisib/GS-1101) – Gilead Sciences

3.2.9 Imbruvica (ibrutinib) – Pharmacyclics/Janssen Biotech

3.2.10 Beleodaq (belinostat) – Spectrum Pharmaceuticals

3.2.11 Poteligeo (mogamulizumab) – Kyowa Hakko Kirin

3.3 Chemotherapies/Regimens

3.3.1 Pixuvri (pixantrone dimaleate) – CTI BioPharma

3.3.2 Treanda (bendamustine) + Rituxan (rituximab)


3.3.4 CVP/R-CVP

3.4 Comparative Efficacy and Safety (Marketed Products)

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at


Mr. Nachiket

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948



Follow us on LinkedIn:

Designed by
Powered by